RecruitingNCT02437396
Oxidative Stress and Inflammatory Biomarkers in Gaucher Disease
Studying Brain inflammatory disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Minnesota
- Principal Investigator
- Reena Kartha, PhD, M.S. CCC-SLPUniversity of Minnesota
- Enrollment
- 34 enrolled
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2015 – 2026
Study locations (1)
- University of Minnesota, Minneapolis, Minnesota, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02437396 on ClinicalTrials.govOther trials for Brain inflammatory disease
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07411612The Association Between Postoperative Inflammatory and Neurological Serum Biomarker Concentrations and Occurrence of Postoperative DeliriumMedical University of Vienna
- RECRUITINGNCT06973837Studying the Neurobiological Mechanisms of Non-specific Chronic Low Back Pain and Chronic Insomnia: a Four-group Cross-sectional StudyVrije Universiteit Brussel
- ENROLLING BY INVITATIONNCT07163156Prolactin, Inflammation, and Parkinson's SeverityÇanakkale Onsekiz Mart University
- RECRUITINGNCT056971597 Tesla MRI Brain Imaging to Decipher Filgotinib's Mode of Analgesic Action in Rheumatoid ArthritisNHS Greater Glasgow and Clyde
- ENROLLING BY INVITATIONPHASE2NCT05350774Immunotherapy for Neurological Post-Acute Sequelae of SARS-CoV-2National Institute of Neurological Disorders and Stroke (NINDS)
- RECRUITINGPHASE2NCT03274375Immunoadsorption Therapy in Managing NMDAR Antibodies EncephalitisAssistance Publique - Hôpitaux de Paris
- ACTIVE NOT RECRUITINGPHASE4NCT04814355The Effect of Celecoxib on Neuroinflammation in MDDStony Brook University
- RECRUITINGNCT02979951Fosfomycin I.v. for Treatment of Severely Infected PatientsInfectopharm Arzneimittel GmbH